Navigation Links
BioLineRx Reports Third Quarter 2013 Financial Results
Date:11/13/2013

BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in late 2013; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study in late 2013.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Secur
'/>"/>

SOURCE BioLineRx Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
2. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
3. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
4. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
5. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
7. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
8. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
9. BioLineRx to Present at 15th International Celiac Disease Symposium
10. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
11. BioLineRx Appoints B. J. Bormann to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Restore Health, ... and compounded pharmaceuticals, announced that it is now ... unique to each individual based upon their particular ... by understanding the interaction between a patient,s genetics ... "We,re very excited to provide this new service ...
(Date:7/24/2014)... Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... First quarter overview: , Revenues of $47.5 million, ... Diluted EPS of $0.21, up 50% over last year,s ... market revenues of $7.2 million, up 20% over last ...
(Date:7/24/2014)... MOUNTAIN VIEW, Calif. , July 24, 2014 ... ), a leading provider of medication and supply ... hold a conference call Thursday, July 31, to ... What:  , Omnicell Second Quarter 2014 earnings ... 2014, 1:30 p.m. PTWho:  , Randall Lipps, chairman, ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
(Date:7/25/2014)... As reported by Wood TV 8 in the article ... a nearly 500-person increase in heroin related overdose deaths in ... 1999 and 2002, the toll increased to 728 during the ... drug users in Michigan have turned to heroin after getting ... price of both substances, noting that an 80-milligram pill can ...
(Date:7/25/2014)... and MOSI officially announced a transformational partnership that will unite ... a difference in the Tampa Bay community. Florida Hospital presented ... support needed to keep the science center moving forward. ... Theatre from film to a state-of-the-art digital 3D projection system. ... state of Florida, and it is one of the first ...
(Date:7/25/2014)... July 25, 2014 Merrill Corporation ... technology-enabled services for the financial, legal, healthcare and ... data room business, Merrill DataSite, has been recognized ... by GrowthBusiness at the M&A Awards 2014 event. ... achievements of entrepreneurs, management teams, advisors and financiers ...
(Date:7/25/2014)... North York, ON (PRWEB) July 25, 2014 A ... St. Michael’s Hospital revealed that 39 percent of all children ... see a dentist. , The survey looked at 2,505 children during ... were all around four years of age. The final result ... had any dental care. Many of these children were from lower-income ...
(Date:7/25/2014)... Parker Waichman LLP, a national law ... on a recent tobacco lawsuit in which a Florida ... in punitive damages. Cynthia Robinson brought the lawsuit against ... is Cynthia Robinson v. R.J. Reynolds Tobacco Company and ... Court, Escambia County, Florida; Case Number 2008 CA 000098. ...
Breaking Medicine News(10 mins):Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3
... sickest still going without, study finds , , TUESDAY, April 22 ... in some improvements for seniors but no real revolution in ... Medicare beneficiaries are less likely to forego basic needs such ... are still skipping meds due to burdensome costs. , "It,s ...
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), ... invasive treatment of peripheral vascular disease,explains interruption of ... 2:00 p.m. PT/5:00 p.m./ET. As a result of ... place as planned., Interested parties are encouraged ...
... Spreading rumors and gossiping may not cause bruises or ... type of bullying could linger into early adulthood, a ... a study of 210 college students, UF researchers discovered ... adolescence and depression and anxiety in early adulthood, according ...
... People with bipolar,disorder and depression can find hope ... Health Care Decision Support system, available,through the Web site ... resources to support health decisions including:, -- ... depression;, -- links to online and ...
... ... wellness, CHICAGO, ... the fourth annual Health at Work Award, honoring,organizations who have demonstrated ... the world,s largest,provider of employee assistance programs and worldwide leader in,GuidanceResources ...
... risk greatest week after meds begin , , TUESDAY, April ... drugs are 60 percent more likely to develop pneumonia in ... a new study shows. , The risk is greatest during ... gradually decreases, say Dutch researchers. , "The risk of developing ...
Cached Medicine News:Health News:Medicare Prescription Drug Benefit Shows Mixed Results 2Health News:Medicare Prescription Drug Benefit Shows Mixed Results 3Health News:Social form of bullying linked to depression, anxiety in adults 2Health News:Social form of bullying linked to depression, anxiety in adults 3Health News:HAP Offers Web-Based Support for Depression and Bipolar Disorder 2Health News:HAP Offers Web-Based Support for Depression and Bipolar Disorder 3Health News:ComPsych Launches Fourth Annual Health at Work(SM) Award Call for Entries 2Health News:Antipsychotic Drugs Linked to Pneumonia in Elderly 2
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
Medicine Products: